A phase i study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 2, 2010, Pages 287-294

  Cohen, Steven J ^a   Zalupski, Mark M ^b   Modiano, Manuel R ^c   Conkling, Paul ^d   Patt, Yehuda Z ^e   Davis, Peg ^f   Dorr, Robert T ^f,g   Boytim, Michelle L ^g   Hersh, Evan M ^f,g  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Arizona Clinical Research Center   (United States)

^d Virginia Surgical Associates   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g AmpliMed Corporation   (United States)

Author keywords

Gemcitabine; Imexon; Pancreatic cancer; Phase I clinical trial

Indexed keywords

GEMCITABINE; IMEXON; 4 IMINO 1,3 DIAZABICYCLO(3.1.0)HEXAN 2 ONE; 4-IMINO-1,3-DIAZABICYCLO(3.1.0)HEXAN-2-ONE; ALKANONE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYSTINE; DEOXYCYTIDINE; DRUG DERIVATIVE; THIOL DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE DIARRHEA; ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD TOXICITY; BLOOD TRANSFUSION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; LEUKOCYTE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NEUTROPHIL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SIDE EFFECT; SYNCOPE; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOSIS; THROMBUS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; ADENOCARCINOMA; AGED; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; HALF LIFE TIME; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; COHORT STUDIES; CYSTINE; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HEXANONES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SULFHYDRYL COMPOUNDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953073888     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1162-y     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966
4. Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE (1992) Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst 84:1238-1244
5. Dorr RT, Raymond MA, Landowski TH, Roman NO, Fukushima S (2005) Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines. Int J Gastrointest Cancer 36:15-28
6. Samulitis BK, Landowski TH, Dorr RT (2009) Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells. Invest New Drugs 27(1):89-98
7. Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT (2000) Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 60:749-758
8. Pourpak A, Meyers RO, Samulitis BK, Sherry Chow HH, Kepler CY, Raymond MA, Hersh E, Dorr RT (2006) Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anticancer Drugs 17:1179-1184
9. Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow HH, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr R (2007) Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol 25:1779-1784
10. Storniolo AM, Allerheiligen SR, Pearce HL (1997) Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncl 24:S7-2-S7-7
11. Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R (2009)Aphase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs [e-pub ahead of print]
12. Samlowski WE, Weber JS, Gonzalez R et al (2008) Phase I/II study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with metastatic malignant melanoma. J Clin Oncol 26 (May 20 Suppl; abstr 9066)
13. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR (2003) Phase III comparison of two irinotecan dosing regimens second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807-814
14. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275
15. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB 3rd (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778-3785
16. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783
17. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498